Sidley Represents Nuvalent in Pricing of US$500 Million Public Offering

Sidley represented Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, in its US$500 million underwritten public offering of 4,950,496 shares of its Class A common stock at a price to the public of US$101.00 per share. The offering priced on November 18, 2025 and closed on November 20, 2025. J.P. Morgan, Jefferies, TD Cowen, and Cantor are serving as joint book-running managers for the offering.

The selling stockholders – Deerfield Healthcare Innovations Fund, L.P. and Deerfield Private Design Fund IV, L.P. – have granted the underwriters a 30-day option to purchase up to an additional 742,574 shares at the public offering price.

The Sidley team was led by Rosemary Reilly and Craig Hilts (Emerging Companies and Venture Capital) and included Torrey Cope and Kevin Sforza (Food, Drug and Medical Device); Tanner Groce (Energy and Infrastructure); Emily Ivers (Emerging Companies and Venture Capital); and Talbott Paulsen (M&A).